Compare Fox Corp Class B (FOX) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class B vs Zoetis Inc — how do they compare? Fox Corp Class B trades at $59.02 (market cap $25.36B), while Zoetis Inc trades at $73.27 (market cap $30.20B). The key difference: Zoetis Inc is the larger of the two by market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class B for 75 Days and Zoetis Inc for 70 Days on average.
| FOX | ZTS | |
|---|---|---|
Market Cap | $25.36B | $30.20B |
Volume | 886,620 | 6,175,327 |
Sector | Media | Health |
52-Week High | $67.76 | $147.53 |
52-Week Low | $44.39 | $69.09 |
Typical Hold Time | 75 Days | 70 Days |
Enterprise Value | $28.72B | $37.76B |
Dividend Yield | 1.02% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOX trades at $55.98, up 0.72% today, with a bearish technical signal but strong fundamentals. Recent earnings beats in Q4 2025, Q1 2026, and Q2 2026, alongside a net income margin of 13.88% in 2025, highlight robust profitability. The company maintains solid cash flow and a healthy balance sheet with $5.35B in cash. Analyst consensus is a Buy with a $84.75 price target, though technical indicators show resistance near $57.
The stock presents a value opportunity with a P/E of 14.59 and P/S of 1.44, supported by earnings growth. Risks include a projected net cash flow decline to -$1.1B in 2026 and bearish technical trends. Upside potential exists if the company meets Q3 2026 EPS expectations of 2.06, but investors should monitor cash flow trends and competitive pressures in the media sector.
Zoetis (ZTS) trades at $71.55, showing modest daily gains of 0.32% amid a challenging market environment. The stock faces bearish technical signals with mixed quarterly earnings performance - beating expectations in Q2 2026 but missing in Q1. Strong fundamentals persist with 71.67% gross margins and 27.69% net income margins, though recent headwinds include U.S. companion animal market weakness and increased competition in key therapeutic areas. The company maintains robust cash flow generation with $2.9 billion from operations in 2025.
Despite near-term pressures, ZTS presents value opportunity with attractive valuation at 11.67 P/E ratio and consensus price target of $87.33 suggesting 22% upside. Risks include ongoing competitive pressures and U.S. market softness, but industry-leading profitability and international growth provide stability. Analyst sentiment remains positive with no sell ratings among 32 covering firms, though technical indicators suggest cautious near-term positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
